These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17197488)

  • 1. PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension.
    Deibert P; Bremer H; Roessle M; Kurz-Schmieg AK; Kreisel W
    Eur Respir J; 2007 Jan; 29(1):220-1. PubMed ID: 17197488
    [No Abstract]   [Full Text] [Related]  

  • 2. Tadalafil as treatment for idiopathic pulmonary arterial hypertension.
    de Carvalho AC; Hovnanian AL; Fernandes CJ; Lapa M; Jardim C; Souza R
    Arq Bras Cardiol; 2006 Nov; 87(5):e195-7. PubMed ID: 17396193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
    Ghofrani HA; Grimminger F
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sildenafil in pulmonary hypertension.
    Nanivadekar A
    Indian Heart J; 2003; 55(3):285; author reply 285. PubMed ID: 14560947
    [No Abstract]   [Full Text] [Related]  

  • 5. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
    Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
    Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sildenafil in primary pulmonary hypertension.
    Prasad S; Wilkinson J; Gatzoulis MA
    N Engl J Med; 2000 Nov; 343(18):1342. PubMed ID: 11183578
    [No Abstract]   [Full Text] [Related]  

  • 7. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
    Shabsigh R; Seftel AD; Rosen RC; Porst H; Ahuja S; Deeley MC; Garcia CS; Giuliano F
    Urology; 2006 Oct; 68(4):689-96. PubMed ID: 17070333
    [No Abstract]   [Full Text] [Related]  

  • 8. Sildenafil citrate therapy for pulmonary arterial hypertension.
    Izbicki G; Rosengarten D; Picard E
    N Engl J Med; 2006 Mar; 354(10):1091-3; author reply 1091-3. PubMed ID: 16528809
    [No Abstract]   [Full Text] [Related]  

  • 9. Phosphodiesterase inhibitors for pulmonary hypertension.
    Galiè N; Rubin LJ; Simonneau G
    N Engl J Med; 2010 Feb; 362(6):559-60; author reply 560. PubMed ID: 20175298
    [No Abstract]   [Full Text] [Related]  

  • 10. Sildenafil citrate therapy for pulmonary arterial hypertension.
    Kuschner WG
    N Engl J Med; 2006 Mar; 354(10):1091-3; author reply 1091-3. PubMed ID: 16528810
    [No Abstract]   [Full Text] [Related]  

  • 11. PDE-5 inhibitors: current status and future trends.
    Masson P; Lambert SM; Brown M; Shabsigh R
    Urol Clin North Am; 2005 Nov; 32(4):511-25, viii. PubMed ID: 16291042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary hypertension in older children: new approaches and therapies.
    Abman SH
    Paediatr Respir Rev; 2006; 7 Suppl 1():S177-9. PubMed ID: 16798555
    [No Abstract]   [Full Text] [Related]  

  • 13. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
    Tinel H; Stelte-Ludwig B; Hütter J; Sandner P
    BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Erectile dysfunction (ED) and diabetes mellitus].
    Takahashi Y
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():553-7. PubMed ID: 15999768
    [No Abstract]   [Full Text] [Related]  

  • 15. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study.
    Mukhopadhyay S; Sharma M; Ramakrishnan S; Yusuf J; Gupta MD; Bhamri N; Trehan V; Tyagi S
    Circulation; 2006 Oct; 114(17):1807-10. PubMed ID: 17030688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic neuropathy - a further indication for phosphodiesterase type 5 inhibitors?
    Oliver JJ
    Int J Clin Pract; 2006 Sep; 60(9):1026-7. PubMed ID: 16939541
    [No Abstract]   [Full Text] [Related]  

  • 17. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic GMP and phosphodiesterase 5 inhibitor therapies: what's on the horizon?
    Lincoln TM
    Mol Pharmacol; 2004 Jul; 66(1):11-3. PubMed ID: 15213291
    [No Abstract]   [Full Text] [Related]  

  • 19. Epistaxis after PDE-5 inhibitors misuse.
    Pomara G; Morelli G; Menchini-Fabris F; Dinelli N; Campo G; LiGuori G; Selli C
    Int J Impot Res; 2006; 18(2):213-4. PubMed ID: 16107867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
    Hotston M; Shukla N; Bloor J; Persad R; Jeremy JY
    BJU Int; 2006 Dec; 98(6):1331-2. PubMed ID: 17125493
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.